Evidence map›Paper›PMID 23698292›Full record

ArticleJournal of virology2013

Improving the effectiveness of artificial microRNA (amiR)-mediated resistance against Turnip mosaic virus by combining two amiRs or by targeting highly conserved viral genomic regions.

Guillaume Lafforgue, Fernando Martínez, Qi-Wen Niu, Nam-Hai Chua, José-Antonio Daròs, Santiago F Elena

Abstract read
In one paragraph

Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. RNA silencing: the future potential strategy for engineering virus resistance in plants.Physiology and molecular biology of plants : an international journal of functional plant biology · 2025
    Review
  3. Review
  4. Artificial miRNAs and target-mimics as potential tools for crop improvement.Physiology and molecular biology of plants : an international journal of functional plant biology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Optimized RNA-Silencing Strategies forPlants (Basel, Switzerland) · 2021
    Article
  9. Resistance to Turnip Mosaic Virus in the FamilyThe plant pathology journal · 2021
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Variability in the durability of CRISPR-Cas immunity.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019
    Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guillaume LafforgueInstituto de Biología Molecular y Celular de Plantas, Consejo Superior de Investigaciones Científicas-Universitat Politècnica de València, València, Spain.
Fernando Martínez
Qi-Wen Niu
Nam-Hai Chua
José-Antonio Daròs
Santiago F Elena

Funding

SPECIAL POSTDOCTORAL RESEARCH PROGRAM IN AIDST22TW000015 · FIC · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SCOTT, GWENDOLYN B. · 1988 to 1999
–
FIC NIH HHS T22 TW000015
6 · The paper itself

Abstract

A drawback of recent antiviral therapies based on the transgenic expression of artificial microRNAs (amiRs) is the ease with which viruses generate escape mutations. Here, we show two alternative strategies for improving the effectiveness of resistance in plants. First, we expressed two amiRs complementary to independent targets in the viral genome, and second, we designed amiRs complementary to highly conserved RNA motifs in the viral genome.

Indexed as

ArabidopsisBayes TheoremConserved SequenceDisease ResistanceDNA, ComplementaryGenome, ViralLinear ModelsLogistic ModelsMicroRNAsPlant DiseasesPotyvirusDNA, ComplementaryMicroRNAs

Identifiers

PMID23698292
PMCPMC3700214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.